NCT00581438CompletedNot Applicable
Actual Approach to Treatment of Haemophilia A and B in Spain
Wyeth is now a wholly owned subsidiary of Pfizer0 sites52 target enrollmentStarted: June 2007Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 52
- Primary Endpoint
- Analyze the clinical and therapeutic approach to treament of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.
Study Overview
Brief Summary
Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain.
Detailed Description
Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.
Assess haemophilia A or B patient profile, study different kinds of hanitual clinical treatment of haemophilia A and B patients, and estimate the kind of treatment and dosage units used per year in patients under habitual clinical practice conditions.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Haemophilia A or B patients of any age
- •Written informed consent
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Analyze the clinical and therapeutic approach to treament of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.
Time Frame: 3 months
Secondary Outcomes
- Assess haemophilia A or B patient profile, study different kinds of habitual clinical treatment of haemophilia A and B patients, and estimate the dosage units used per year in patients under habitual clinical practice conditions.(3 months)
Investigators
Similar Trials
Completed
Not Applicable
Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in FranceHemophilia ANCT05450640Hospices Civils de Lyon176
Completed
Not Applicable
Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in FranceHemophilia ANCT05449197Hospices Civils de Lyon363
Not yet recruiting
Not Applicable
Patterns of Hemophilia Care in Assiut Children PatientsHemophilia BHemophilia ANCT05980377Assiut University60
Recruiting
Not Applicable
Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)Hemophilia BHemophilia ANCT06158334Hospices Civils de Lyon400
Completed
Phase 3
Assessing Experiences With Hemophilia A and B: Patient and Caregiver InterviewsCTRI/2021/08/035630Sanofi Aventis Groupe14